Evidence map›Paper›PMID 27358388›Full record

ArticleJournal of biomolecular screening2016

Identification of Novel Inhibitors of the Type I Interferon Induction Pathway Using Cell-Based High-Throughput Screening.

Zoe O Gage, Andri Vasou, David W Gray, Richard E Randall, Catherine S Adamson

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomolecular screening, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zoe O GageSchool of Biology, University of St Andrews, St Andrews, Fife, UK Biomedical Sciences Research Complex (BSRC), University of St Andrews, St Andrews, Fife, UK.
Andri VasouSchool of Biology, University of St Andrews, St Andrews, Fife, UK Biomedical Sciences Research Complex (BSRC), University of St Andrews, St Andrews, Fife, UK.
David W GrayDrug Discovery Unit, University of Dundee, Dundee, UK.
Richard E RandallSchool of Biology, University of St Andrews, St Andrews, Fife, UK Biomedical Sciences Research Complex (BSRC), University of St Andrews, St Andrews, Fife, UK.
Catherine S AdamsonSchool of Biology, University of St Andrews, St Andrews, Fife, UK Biomedical Sciences Research Complex (BSRC), University of St Andrews, St Andrews, Fife, UK csa21@st-andrews.ac.uk.
University of St Andrews · GBUniversity of Dundee · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Production of type I interferon (IFN) is an essential component of the innate immune response against invading pathogens. However, its production must be tightly regulated to avoid harmful effects. Compounds that modulate the IFN response are potentially valuable for a variety of applications due to IFN's beneficial and detrimental roles. We developed and executed a cell-based high-throughput screen (HTS) targeting components that participate in and/or regulate the IRF3 and nuclear factor (NF)-κB branches of the IFN induction pathway. The assay detects activation of the IFN induction pathway via an enhanced green fluorescent protein (eGFP) reporter gene under the control of the IFNβ promoter and was optimized, miniaturized, and demonstrated suitable for HTS as robust Z' factor scores of >0.6 were consistently achieved. A diversity screening set of 15,667 small molecules was assayed and two novel hit compounds validated that specifically inhibit the IFN induction pathway. We demonstrate that one of these compounds acts at or upstream of IRF3 phosphorylation. A second cell-based assay to detect activation of the IFN signaling (Jak-Stat) pathway via an eGFP reporter gene under the control of an IFN-stimulated response element (ISRE) containing MxA promoter also performed well (robust Z' factor >0.7) and may therefore be similarly used to identify small molecules that modulate the IFN signaling pathway.

Indexed as

Green Fluorescent ProteinsHigh-Throughput Screening AssaysHumansImmunity, InnateInterferon Regulatory Factor-3Interferon Type INF-kappa BSignal TransductionSmall Molecule LibrariesGreen Fluorescent ProteinsInterferon Regulatory Factor-3Interferon Type IIRF3 protein, humanNF-kappa BSmall Molecule Librarieshigh-throughput screen (HTS)innate immunityinterferonIRF3NF-κB

Identifiers

PMID27358388
PMCPMC5030734
OpenAlexW2473238041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.